The role of tivozanib in advanced renal cell carcinoma therapy

Bernard Escudier, Camillo Porta, Tim Eisen, Jonathan Belsey, Damilola Gibson, Jonathan Morgan, Robert Motzer

Research output: Contribution to journalArticle

Abstract

INTRODUCTION: The efficacy of VEGF-targeting therapies in clinical trials led to their recommendation in clinical guidelines for use across the advanced or metastatic renal cell carcinoma (RCC) treatment landscape, however, tolerability (including off-target effects) has remained a challenge. Tivozanib is a selective inhibitor of all three VEGFRs, with limited off-target interaction, which demonstrates efficacy with improved tolerability relative to multikinase VEGFR-TKIs. Areas covered: Covered here is the clinical development of tivozanib in advanced RCC, including the pivotal Phase III, multicenter, open-label, randomized clinical study comparing tivozanib with sorafenib for the treatment of VEGF- and mTOR therapy-naïve advanced RCC patients. Also covered are ongoing trials, exploring the efficacy and safety of tivozanib in the setting of refractory disease and the utility of tivozanib in combination with checkpoint inhibitors for advanced RCC. Combination of a VEGFR-TKI and immunotherapy is promising in advanced RCC, if the treatment regimens have acceptable tolerability. Here the selectivity of tivozanib may contribute to an acceptable tolerability profile when used in combination therapy. Expert commentary: The approval of tivozanib provides an additional option for the first-line treatment of advanced or metastatic RCC patients in Europe and allows use of a VEGFR-TKI with selectivity for VEGFRs in this setting.

Original languageEnglish
Pages (from-to)1113-1124
Number of pages12
JournalExpert Review of Anticancer Therapy
Volume18
Issue number11
DOIs
Publication statusPublished - Nov 2018

Fingerprint

Cell- and Tissue-Based Therapy
Renal Cell Carcinoma
Vascular Endothelial Growth Factor A
Therapeutics
tivozanib
Immunotherapy
Clinical Trials
Guidelines
Safety

Cite this

Escudier, B., Porta, C., Eisen, T., Belsey, J., Gibson, D., Morgan, J., & Motzer, R. (2018). The role of tivozanib in advanced renal cell carcinoma therapy. Expert Review of Anticancer Therapy, 18(11), 1113-1124. https://doi.org/10.1080/14737140.2018.1508348

The role of tivozanib in advanced renal cell carcinoma therapy. / Escudier, Bernard; Porta, Camillo; Eisen, Tim; Belsey, Jonathan; Gibson, Damilola; Morgan, Jonathan; Motzer, Robert.

In: Expert Review of Anticancer Therapy, Vol. 18, No. 11, 11.2018, p. 1113-1124.

Research output: Contribution to journalArticle

Escudier, B, Porta, C, Eisen, T, Belsey, J, Gibson, D, Morgan, J & Motzer, R 2018, 'The role of tivozanib in advanced renal cell carcinoma therapy', Expert Review of Anticancer Therapy, vol. 18, no. 11, pp. 1113-1124. https://doi.org/10.1080/14737140.2018.1508348
Escudier B, Porta C, Eisen T, Belsey J, Gibson D, Morgan J et al. The role of tivozanib in advanced renal cell carcinoma therapy. Expert Review of Anticancer Therapy. 2018 Nov;18(11):1113-1124. https://doi.org/10.1080/14737140.2018.1508348
Escudier, Bernard ; Porta, Camillo ; Eisen, Tim ; Belsey, Jonathan ; Gibson, Damilola ; Morgan, Jonathan ; Motzer, Robert. / The role of tivozanib in advanced renal cell carcinoma therapy. In: Expert Review of Anticancer Therapy. 2018 ; Vol. 18, No. 11. pp. 1113-1124.
@article{5b1e4b79ca26489e9018a45558c18038,
title = "The role of tivozanib in advanced renal cell carcinoma therapy",
abstract = "INTRODUCTION: The efficacy of VEGF-targeting therapies in clinical trials led to their recommendation in clinical guidelines for use across the advanced or metastatic renal cell carcinoma (RCC) treatment landscape, however, tolerability (including off-target effects) has remained a challenge. Tivozanib is a selective inhibitor of all three VEGFRs, with limited off-target interaction, which demonstrates efficacy with improved tolerability relative to multikinase VEGFR-TKIs. Areas covered: Covered here is the clinical development of tivozanib in advanced RCC, including the pivotal Phase III, multicenter, open-label, randomized clinical study comparing tivozanib with sorafenib for the treatment of VEGF- and mTOR therapy-na{\"i}ve advanced RCC patients. Also covered are ongoing trials, exploring the efficacy and safety of tivozanib in the setting of refractory disease and the utility of tivozanib in combination with checkpoint inhibitors for advanced RCC. Combination of a VEGFR-TKI and immunotherapy is promising in advanced RCC, if the treatment regimens have acceptable tolerability. Here the selectivity of tivozanib may contribute to an acceptable tolerability profile when used in combination therapy. Expert commentary: The approval of tivozanib provides an additional option for the first-line treatment of advanced or metastatic RCC patients in Europe and allows use of a VEGFR-TKI with selectivity for VEGFRs in this setting.",
author = "Bernard Escudier and Camillo Porta and Tim Eisen and Jonathan Belsey and Damilola Gibson and Jonathan Morgan and Robert Motzer",
year = "2018",
month = "11",
doi = "10.1080/14737140.2018.1508348",
language = "English",
volume = "18",
pages = "1113--1124",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "11",

}

TY - JOUR

T1 - The role of tivozanib in advanced renal cell carcinoma therapy

AU - Escudier, Bernard

AU - Porta, Camillo

AU - Eisen, Tim

AU - Belsey, Jonathan

AU - Gibson, Damilola

AU - Morgan, Jonathan

AU - Motzer, Robert

PY - 2018/11

Y1 - 2018/11

N2 - INTRODUCTION: The efficacy of VEGF-targeting therapies in clinical trials led to their recommendation in clinical guidelines for use across the advanced or metastatic renal cell carcinoma (RCC) treatment landscape, however, tolerability (including off-target effects) has remained a challenge. Tivozanib is a selective inhibitor of all three VEGFRs, with limited off-target interaction, which demonstrates efficacy with improved tolerability relative to multikinase VEGFR-TKIs. Areas covered: Covered here is the clinical development of tivozanib in advanced RCC, including the pivotal Phase III, multicenter, open-label, randomized clinical study comparing tivozanib with sorafenib for the treatment of VEGF- and mTOR therapy-naïve advanced RCC patients. Also covered are ongoing trials, exploring the efficacy and safety of tivozanib in the setting of refractory disease and the utility of tivozanib in combination with checkpoint inhibitors for advanced RCC. Combination of a VEGFR-TKI and immunotherapy is promising in advanced RCC, if the treatment regimens have acceptable tolerability. Here the selectivity of tivozanib may contribute to an acceptable tolerability profile when used in combination therapy. Expert commentary: The approval of tivozanib provides an additional option for the first-line treatment of advanced or metastatic RCC patients in Europe and allows use of a VEGFR-TKI with selectivity for VEGFRs in this setting.

AB - INTRODUCTION: The efficacy of VEGF-targeting therapies in clinical trials led to their recommendation in clinical guidelines for use across the advanced or metastatic renal cell carcinoma (RCC) treatment landscape, however, tolerability (including off-target effects) has remained a challenge. Tivozanib is a selective inhibitor of all three VEGFRs, with limited off-target interaction, which demonstrates efficacy with improved tolerability relative to multikinase VEGFR-TKIs. Areas covered: Covered here is the clinical development of tivozanib in advanced RCC, including the pivotal Phase III, multicenter, open-label, randomized clinical study comparing tivozanib with sorafenib for the treatment of VEGF- and mTOR therapy-naïve advanced RCC patients. Also covered are ongoing trials, exploring the efficacy and safety of tivozanib in the setting of refractory disease and the utility of tivozanib in combination with checkpoint inhibitors for advanced RCC. Combination of a VEGFR-TKI and immunotherapy is promising in advanced RCC, if the treatment regimens have acceptable tolerability. Here the selectivity of tivozanib may contribute to an acceptable tolerability profile when used in combination therapy. Expert commentary: The approval of tivozanib provides an additional option for the first-line treatment of advanced or metastatic RCC patients in Europe and allows use of a VEGFR-TKI with selectivity for VEGFRs in this setting.

U2 - 10.1080/14737140.2018.1508348

DO - 10.1080/14737140.2018.1508348

M3 - Article

VL - 18

SP - 1113

EP - 1124

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 11

ER -